Literature DB >> 31270751

Epidemiology and Outcome Determinants of Staphylococcus aureus Bacteremia Revisited: A Population-Based Study.

John C Lam1, Daniel B Gregson2, Stephen Robinson3, Ranjani Somayaji4, John M Conly5, Michael D Parkins6.   

Abstract

PURPOSE: Staphylococcus aureus bacteremia (SAB) is associated with significant morbidity and mortality. We sought to re-define the burden, epidemiology and mortality-associated risk factors of SAB in a large Canadian health region.
METHODS: Residents (> 18 years) experiencing SAB from 2012 to 2014 were assessed. Incidence rates were calculated using civic census results. Factors associated with 30-day mortality were determined through multivariate logistic regression. Incidence and risk factors for SAB were compared to 2000-2006 data.
RESULTS: 780 residents experienced 840 episodes of SAB (MRSA; 20%). Incidence rates increased from 23.5 to 32.0 cases/100,000 from 2012 to 2014; [IRR 1.15 (95% CI 1.07-1.23); p < 0.001]. Compared to a decade ago, incidence of SAB has increased [IRR 1.28 (95% CI 1.21-1.36); p < 0.001] despite minimal change in nosocomial SAB. MRSA proportion did not change through the study (p = 0.3), but did increase relative to a decade ago (20.0% vs 11.0%, p < 0.001). Thirty-day mortality rates were 30.6% and 21.3% for MRSA and MSSA, respectively (p = 0.01), similar to rates from 2000 to 2006. Several clinical, demographic, and biochemical factors were independently associated with SAB mortality.
CONCLUSIONS: SAB is common within our population resulting in significant mortality. Incidence rates of SAB are increasing in our health region; however, 30-day mortality rates remain stable.

Entities:  

Keywords:  Bacteremia; Epidemiology; MRSA; Mortality; Staphylococcus aureus

Mesh:

Year:  2019        PMID: 31270751     DOI: 10.1007/s15010-019-01330-5

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

Review 1.  Incidence Trends and Epidemiology of Staphylococcus aureus Bacteremia: A Systematic Review of Population-Based Studies.

Authors:  Joya-Rita Hindy; Juan A Quintero-Martinez; Alexander T Lee; Christopher G Scott; Danielle J Gerberi; Maryam Mahmood; Daniel C DeSimone; Larry M Baddour
Journal:  Cureus       Date:  2022-05-29

2.  Comparison of Clinical Outcomes for Glycopeptides and Beta-Lactams in Methicillin-Susceptible Staphylococcus Aureus Bloodstream Infections.

Authors:  Yeon Ju La; Hye Rim Kim; Dong Hyun Oh; Jin Young Ahn; Yong Chan Kim
Journal:  Yonsei Med J       Date:  2022-07       Impact factor: 3.052

3.  Longitudinal evaluation of risk factors and outcomes of blood stream infections due to Staphylococcus species in persons with HIV: An observational cohort study.

Authors:  Raynell Lang; M John Gill; Quang Vu; Jeannine Viczko; Chris Naugler; Deirdre Church
Journal:  EClinicalMedicine       Date:  2020-12-05

Review 4.  The Role of Macrophages in Staphylococcus aureus Infection.

Authors:  Grace R Pidwill; Josie F Gibson; Joby Cole; Stephen A Renshaw; Simon J Foster
Journal:  Front Immunol       Date:  2021-01-19       Impact factor: 7.561

5.  Persistent Methicillin-Susceptible Bacteremia Rapidly Cleared with Cefazolin and Ertapenem Combination Therapy in a Patient with COVID-19.

Authors:  Dan Ilges; Gayathri Krishnan; Elvin Geng
Journal:  Case Rep Infect Dis       Date:  2022-04-20

6.  Risk Factors and Outcomes of Bloodstream Infections Among People With Human Immunodeficiency Virus: A Longitudinal Cohort Study From 2000 to 2017.

Authors:  Raynell Lang; M John Gill; Jeannine Viczko; Christopher Naugler; Deirdre Church
Journal:  Open Forum Infect Dis       Date:  2022-08-03       Impact factor: 4.423

7.  A truncated peptide Spgillcin177-189 derived from mud crab Scylla paramamosain exerting multiple antibacterial activities.

Authors:  Xiaofei Wang; Xiao Hong; Fangyi Chen; Ke-Jian Wang
Journal:  Front Cell Infect Microbiol       Date:  2022-08-02       Impact factor: 6.073

8.  Early differentiation between uncomplicated and complicated Staphylococcus aureus bacteraemia: Potential value and limitations of a clinical risk score.

Authors:  Merel M C Lambregts; Eva B D Molendijk; Soufian Meziyerh; Emile F Schippers; Nathalie M Delfos; Masja Leendertse; Alexandra T Bernards; Leo G Visser; Olaf M Dekkers; Mark G J de Boer
Journal:  Int J Clin Pract       Date:  2020-07-14       Impact factor: 3.149

9.  Decrease in All-Cause 30-Day Mortality after Bacteraemia over a 15-Year Period: A Population-Based Cohort Study in Denmark in 2000-2014.

Authors:  Mona Katrine Alberthe Holm; Filip Jansåker; Kim Oren Gradel; Rikke Thoft Nielsen; Christian Østergaard Andersen; Jens Otto Jarløv; Henrik Carl Schønheyder; Jenny Dahl Knudsen
Journal:  Int J Environ Res Public Health       Date:  2021-06-02       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.